Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.48 |
| ▸ | GRM5 | P41594 | 11/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1577504 | 1.00 | NAMPT (0.53) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL23554461 | 0.89 | TNF (0.44) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL29550046 | 0.89 | TNF (0.44) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL29891644 | 0.85 | NAMPT (0.55) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL29840385 | 0.85 | NAMPT (0.55) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL15095872 | 0.85 | NAMPT (0.55) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL29840400 | 0.85 | NAMPT (0.55) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL23306173 | 0.85 | NAMPT (0.55) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL14141902 | 0.85 | CYP11B2 (0.52) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL12558047 | 0.84 | NAMPT (0.54) | NAMPTCYP11B2GRM1GRM5PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4079734-B1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| CN-113423708-B | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2025-04-22 | — | — | CN | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4079734-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | NAMPT 1468/4885CYP11B2 58/4885GRM1 3433/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | NAMPT 3526/4885CYP11B2 94/4885GRM1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.